December 1, 2003

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Dysregulation of BLyS over extended periods of time is common in patients with SLE. Neutralization of BLyS activity with an appropriate BLyS antagonist may be therapeutically beneficial.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Stohl et al. (Mon,) studied this question.

synapsesocial.com/papers/69d7002299397875bbaa80a4 https://doi.org/https://doi.org/10.1002/art.11354

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator2003 · 488 citations
2Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus2001 · 730 citations
3Characterization of a New Member of the TNF Family Expressed on Antigen Presenting Cells1999 · 99 citations
4Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus2001 · 1,259 citations
5BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth1999 · 1,328 citations

Preguntar a la IA

Me gusta

Guardar